Nicandro Durante
Management
Good morning everyone and welcome to British American Tobacco 2017 Preliminary Results Presentation. I'm Nicandro Durante, Chief Executive Officer of American Tobacco and with me this morning is Ben Stevens, Finance Director. As always, a warm welcome to those of you who are listening on the conference call or watching via our website, bat.com. As usual, after taking you through the results presentation, there will be an opportunity for you to ask questions. Before I start the presentation, I will take you that you have all seen and read the disclaimer. 2017 was a transformational year for BAT, not only did they deliver on the financials, but we also completed our acquisition of Reynolds America, the largest tobacco deal in history. This is a transformational deal providing BAT of access to one of the most profitable markets in the world, our unique portfolio brands and products and further it reinforces the long-term sustainability of our commitment to high-single figure EPS growth. I’m proud to say that once again we have delivered on this commitment. At current rate, adjusted EPS grew 15% and was that 10% on a constant currency basis. This was driven by the continued good performance of our combustible business, with the GDBs the newly acquired U.S. brands and the group’s overall growing share. Reported EPS was up over 600% mainly due to a counter treatment of the Reynolds' acquisition. Ben will talk more about this later. 2017 was also a transformation year for us in NGPs. Our expanded vapor business reached an annualized revenue of nearly £300 million and a strong growth of glo Japan drove THP revenue from zero to over £200 million. In total, the combined NGP business delivered £500 million of group revenue on an annualized basis in 2017, meeting the target we set at our Investor Day in October. We are aiming to grow this to over £1 billion this year and to £5 billion by 2022. I’m confident of substantially increasing exceeding these targets. Our confidence in the future of the business reflecting the 15% increase in the dividend, which announced this morning. 2017 was also an eventful year for the industry. Although we saw higher price in most markets, we also have seen significant exciting increases in the GCC, Russia, Pakistan and Malaysia over recent year. These together is a more aggressive pricing environment in a number of market lead to down trading continued growth in illicit and industry volume decline. Against this challenging backdrop, BAT once again outperformed the industry. Organic cigarette volume including THP was down 2.6% against an industry down around 3.5%. In July, the SDA announced, a consultation for new tobacco regulation proposals. We remain very encouraged by the SDA's recognition of the continued of risk for tobacco products and of Tobacco Harm Reduction as a policy. We have located this printed for 20 years and this reported regulator is key to the transformation of the tobacco industry. However, this is a new complicated area and will take time to get through the process. We await the publication of the advantage notice of proposal rule making and look forward to participate in the consultation process. In Quebec, a judgment for the court of appeal continues to be expected anytime of the transaction cases against our Canadian subsidiary. As I have said before, a wide range of outcome is possible, including a request for leave to appear to the Supreme Court of Canada and the use of Canadian regulations such as [indiscernible]. Finally, at the end of the year the U.S. Corporate Tax Reform plans were approved. As announced earlier this year, this provided and benefit to the 2080 PS of 6%. All things being equal we would expect around half of this to be reinvested in the roll out of NGPs. The highlight of the year was of course our acquisition Reynolds, and I’m delighted to say that the benefits of the deal are already beginning to flow through. With only five months contribution for Reynolds in our numbers and no comparison base available we are unable to giving financial performance commentary on the business. However, what I can say is that Reynolds is performing very well with strong share growth in the second half of the year an integration is progressing smoothly, detailed plans have been drawn up for delivery of the synergies. As we said at the end of the deal, we expect cost synergies of at least $400 million. I’m happy to report that figures are flowing through a little earlier than anticipated and have a already delivered more than $70 million in 2017. This has been driven by the benefits of procurement, the implementation of BAT systems and process and into the Reynolds products and facilities together with the integration of the corporate functions. We remain well on-track to deliver the target of at least $400 million in cost synergies by the end of 2020. In addition, we are combining the capabilities of both organizations to fully strength our global R&D. We are the only Company with a predicated tobacco heating product in the West markets. I’m pleased to say that with special equivalence application for our carbon tipped product has been accepted by the FDA and moved to scientific review. We await a final decision around mid-year. We are also making good progress on the development of our SC application for glo in the U.S. and we are on-track for a submission to be made this month to be followed by MRTP application in due course. Finally, we look forward to the FDA’s response on our MRTP application for Camel Snus and we are awaiting the scheduling of our TPSAC meeting to review the application later this year. The addition of Reynolds for the business give us an industry leading portfolio of brands and products giving these and the growing importance of NGP for the business will have expanded or focused from just the GDBs to include the U.S. drive brands our NGP business and our auto product business in the U.S. and the Nordics. All our tobacco products, like it is in U.S. [indiscernible] news have existing epidemiology demonstrating their potential as reduced-risk products. Together with our NGP, we refer to them as potential reduce risk products. For 2018 our expertise we met is a focus on revenue growth for these expanded drive - portfolio, as this is a key measure of success and has come across all four product categories. These more closely aligns with the our strategy and vision. These expanded portfolio gives BAT and industry leading a range of brands and products expanding the [indiscernible] continue that's second to none. Even with the growing quarters of NGPs a significant proportion of the portfolio remains in the combustible cigarette business, which I'm pleased to say that's continue to perform very well. Overall corporate share grew strongly and was up 14 basis points in 2017 on top of the 50 basis points achieved last year. This was driven by another excellent performance on the GDBs, which grew share by 110 basis points across our key markets aside a U.S. This is now our seventh consecutive year of share growth with corporate share-up of total of 210 basis points over the period and GDBs up 630 basis points over the same period. The U.S. drive brands outperformed in the U.S. industry growing share by 40 basis points. Combined together Newport and NAS are the fastest growing brands in premium. Dunhill held up around the previous segment, but was impacted by down trading and significant exercise increase in many of its key markets including Malaysia, Brazil, Indonesia. However, share was down only 10 basis points. Kent, Lucky Strike, Pall Mall and Rothmans all grew share demonstrated a strength for our differentiated brand portfolio and diverse geographic footprint. Our expanded Drive Brand portfolio includes an exciting portfolio of potentially reduced-risk products. Our Tobacco Heating Products cover electronic carbon tip and hybrid products. In Vapor, we have a wide range of open and close systems and under both Vype and VUSE. Finally, the recent acquisition of Reynolds and Winnington extend the portfolio even further into the growing oral tobacco segment with both tobacco and non-tobacco oral products. BAT now has the widest range of potentially reduced-risk products of any tobacco company in the world, with the capability of addressing the widest range of consumer needs. We are therefore the best place tobacco companies through either transformation of the industry and transition the largest numbers of smokers from traditional cigarettes to potentially reduced-risk products. Glo is already demonstrating this in Japan. Just 12 months after the national rollout, glo already has 4.1% market share in January, despite continued capacity constraints limiting the device to one per store per week. Together with our suppliers we are building device manufacturing capacity rapidly and anticipated ahead unrealized capacity of 25 million units by the end of the year. We expect device capacity to become unconstraint during Q2. Our analyzed consumer capacities are already 15 billion sticks and we are able to increase these to 52 billion sticks by the end of the year. In December, we launched four new narrow-stick variants, which had quickly grown to represent 40% of glo’s sales. Glo now has a widest range of products in the market, with the strong pipeline of innovation, including capsule variant and glo mini following later this year. During 2017, glo was also launched in South Korea, Canada, Russia, Switzerland and most recently, Romania. In South Korea, following its launch in Seoul in August, glo was roll out nationally. Glo continues to grow national share and now reached 0.4%. Selling still has its low impact, but [Technical Difficulty] on marketing model to reinforce our market presence. In our trial markets of Canada and Switzerland, we are continuing to refine our marketing model to address the challenge of extremely smooth communication environments and consumer preferences for stronger cigarettes. Our recent stick launches in Russia and Romania are showing very encouraging early results. During 2018, we have plans to launch glo in additional 40 markets. Having only entered the THP market in December 2016, we have made excellent progress during 2017 and expect to build on this in 2018. We also are continuing to make good progress in the development of our Vapor business in 2017. Excluding the U.S., Vapor revenue was up 30%, mainly driven by acquisition, gross margin improved by 10 percentage points, and we are now on-track for our Vapor business to break even by the end of 2018. We continue to consolidate our leadership position in our key markets. In the UK, our Vapor business maintain a record share in retail of 40%. In Germany, Vype became the number one brand in retail with the record 37% share in the channel and an estimated 10% of the total vapor markets. In France, offtake volume was up a thirds and in Italy, expanded distributions and national coverage driving a significant increasing sales. In the U.S., VUSE grew by 16% of revenue by 29%, following increased distribution of Vype and the launch of [indiscernible]. Commercial performance will be boosted further by the recent launch of VUSE e-commerce platform. Importantly, product performance continue to be highly valued by consumers when tested against direct competitors' products. Our acquisition in Poland and UK have performed well. In Poland, CHIC volumes was up over 20% and the UK, 10 Motives has grown market share and revenue month-on-month. The integration of VIP vape start to change in the U.S., UK is progressing well and a 25% expansion of the footprint is planned for 2018. Finally, the priority for 2018 is our second generation of Vapor products ePen 3 and Raptor both of which are due for launch towards the year-end. During the 2017, consuming incidence in Vapor across our key markets is estimated to had grown around 40%, which sharper rises in category penetration in a number of our emerging markets. Our strong pipeline of second-generation of Vapor product and a growing understanding of Vapor consumers put us in a strong position to capitalize on this growth. Alongside our growing NGP business, our large and successful oral tobacco business in the Nordics and in the larger U.S. market provides a further opportunity for smokers to switch to lower-risk products. In 2017, total revenue for oral tobacco grew 16% to nearly £900 million driven by strong performance in the U.S., Sweden and Norway. In the U.S., Grizzly remains the leader in the growing wintergreen and pouch segments. The brand gain a full point on market share to reach 31.8% 2017 driven by Grizzly Dark styles, limited addition packaging and powerful equity building campaign. In Sweden, we are the fastest growing company adding 170 billion points over the year to reach a share of 10.3% in December. In Norway, share was up 340 business points to a record 6.4% in December driven by the success of Epok, our innovative Snus brands. Across the Nordics we are now the leader in white Snus, the fastest growing segment across the markets with an 85% share of segment. We expect to launch a known tobacco brand in the second half and have plans to expand outside the Nordics with these innovative and profitable products. So in summary, in 2017 we completed the Reynolds acquisition and we made to an extent progressing NGPs and a wider potential reduced-risk products portfolio. Our combustible business continues to perform strongly and regarding this a substantial amount of money in the long-term sustainability of the Group. This was all done while delivering on our committed high single-figure earnings growth and this was a truly a transformational year. I’ll now hand over to Ben who will take you through the details of the results.